Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Quest acquires two Texas labs, 7/17

July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.

Distribution partnership for SpeeDx, Cepheid, 7/17

July 2017—SpeeDx announced an agreement with Cepheid for distribution of its PlexPCR and ResistancePlus molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the U.K., will increase coverage for the ResistancePlus MG test, a CE-IVD test for the sexually transmitted infection Mycoplasma genitalium that combines detection with testing for azithromycin resistance.

OpGen, Thermo Fisher supply agreement , 7/17

July 2017—OpGen has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help health care providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.

Infectious diseases monoclonal antibodies, 7/17

July 2017—The Binding Site’s Immunologicals Group has completed a major expansion to its monoclonal antibody product offerings. In addition to the company’s conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, a number of monoclonal antibodies focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma have been introduced.

Inventory management software, 7/17

October 2017—InvMan, an inventory management software solution from Cove Laboratory Software, automates inventory management by providing direct scanning of vendor reagent barcode labels. Using a portable scanner, the vendor 1-D or 2-D barcode is scanned and uploaded to the reagent database in InvMan.

BioFire unveils Salt Lake City facility, 7/17

July 2017—BioMérieux announced that BioFire Diagnostics, its molecular biology affiliate, celebrated the opening of its Alain Mérieux Center for Molecular Diagnostics facility in Salt Lake City. The facility, home to more than 1,000 employees, is dedicated to the development of FilmArray, BioFire’s molecular PCR multiplex system for the syndromic diagnosis of infectious diseases.

Lung, colon cancer research panels, 7/17

July 2017—Agena Bioscience introduced targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSeek Lung and Colon Panels enable the detection of mutations as low as 0.1 percent minor allele frequency from circulating tumor cells and circulating tumor DNA. The iPlex HS Lung and Colon Panels enable detection of mutations as low as one percent MAF from solid tumor tissue.

von Willebrand factor activity test, 7/17

July 2017—BloodCenter of Wisconsin launched its VWF GPIbM Activity assay, which aims to more accurately measure von Willebrand factor activity. The assay detects qualitative VWF defects, reducing variability and providing more precise, reliable, and sensitive test results.

NMDX acquires Nuclea, offers HER2/neu tests, 7/17

July 2017—NanoMolecularDX announced it has acquired the assets of Nuclea Biotechnologies. Assets include all of the intellectual property, biological material, capital equipment, licenses, FDA approvals and allowances, marketing and customer materials, trademarks, and all relevant scientific data. NMDX began selling in May HER2/neu blood testing kits acquired from Nuclea.

Forensic DNA grade consumables, 7/17

July 2017—Eppendorf introduced its Eppendorf Forensic DNA Grade product line, which complies with the requirements of ISO 18385. This standard specifies requirements for the production of products used in the collection, storage, and analysis of biological material for forensic DNA purposes.

MARKETPLACE

TRENDING